SCHEMBL6997329

SCHEMBL6997329

CCCC(=O)CCCN1CC2CC(C1)CN(CCCC(Oc1ccc(OC)c(OC)c1)c1ccc(C#N)cc1)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.39
HRH3 Q9Y5N1 2/20 0.39
KDM2B Q8NHM5 1/20 0.35
DRD3 P35462 1/20 0.34
MAPT P10636 1/20 0.34
MCHR1 Q99705 1/20 0.34
HRH2 P25021 1/20 0.34
HRH1 P35367 1/20 0.34
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34
HTR1A P08908 2/20 0.33
DRD2 P14416 2/20 0.33
HTR7 P34969 2/20 0.33
HTR6 P50406 2/20 0.33
LMNA P02545 1/20 0.33
HIF1A Q16665 1/20 0.33
ADRA1D P25100 1/20 0.33
ADRA1A P35348 1/20 0.33
ADRA1B P35368 1/20 0.33
GCGR P47871 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6992027 0.91 HRH3 (0.39) SLC6A4HRH3DRD3MAPTMCHR1
SCHEMBL6740792 0.89 SLC6A4 (0.41) SLC6A4HRH3DRD3MAPTMCHR1
SCHEMBL6993367 0.87 HRH3 (0.40) SLC6A4HRH3DRD3MAPTMCHR1
SCHEMBL6990939 0.86 HRH3 (0.42) SLC6A4HRH3KDM2BDRD3MAPT
SCHEMBL7030839 0.86 HRH3 (0.41) SLC6A4HRH3DRD3MAPTMCHR1
SCHEMBL6739004 0.85 POLB (0.40) SLC6A4HRH3DRD3MAPTMCHR1
SCHEMBL6997028 0.85 HRH3 (0.38) SLC6A4HRH3DRD3MAPTMCHR1
SCHEMBL6995417 0.85 SLC6A4 (0.39) SLC6A4HRH3DRD3MAPTMCHR1
SCHEMBL6991661 0.85 HRH3 (0.41) SLC6A4HRH3KDM2BHRH2HRH1
SCHEMBL7028310 0.85 MCHR1 (0.43) SLC6A4HRH3MAPTMCHR1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2003-11-13 US disclosed
EP-1301510-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2003-04-16 EP disclosed
WO-2002004446-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias KCNH1, LBR, CACNA1E SLC6A4 1139/4885HRH3 402/4885KDM2B 3085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.